Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden gene changes could reveal who gets cancer

NCT ID NCT00996710

Knowledge-focused Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study searches for new gene changes (mutations) that appear in cancer patients but not in their healthy parents. By comparing DNA from 1,275 people with certain cancers and their families, researchers hope to find genetic clues that increase cancer risk. The goal is to better understand how these new mutations contribute to cancer and potentially identify people at higher risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help identify people at higher risk for certain cancers by detecting new gene changes that are not inherited.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to immediate clinical changes, and findings may not apply to all cancer types or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,275 people

The number who actually took part.

Start date

Oct 2009

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The majority of eligible probands will be identified prospectively through the clinics of the Clinical Genetics, Medical Oncology and Pediatric Oncology Services of MSKCC by the patient's physician, the protocol investigator, or a research team member.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Proband must have living unaffected biologic mother and father available and eligible for participation in the study with one of the following (both incident and prevalent cases will be collected): * Colorectal cancer diagnosed at or under the age of 50. * Breast cancer diagnosed at or under the age of 45. * Germ cell tumor diagnosed at or under the age of 40. * Pediatric cancer of any type diagnosed at or under the age of 21 * Adult cancer or pre-neoplastic condition of any type diagnosed at or under the age of 40 * Cancer at any age in 2 or more siblings suggestive of a genetic etiology, such as brothers with testicular germ cell tumor or sisters with breast cancer and ovarian cancer * Parents: * Must be the biologic mother and biologic father of affected proband. * Must have (by self-report) no history of cancer other than non-melanomatous skin cancer or cervical cancer in situ except in the case of inclusion criteria #6.. * In certain clinical situations, parent(s) with cancer may be included at the discretion of the Principal Investigator, if the Principal Investigator deems that the etiology of cancer in the parent(s) and proband are biologically unrelated. * Sibling(s): * Must be age 18 or older and have same biologic parents as proband. Exclusion Criteria: * Known genetic mutation in proband or a family history that is indicative of hereditary cancer susceptibility.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm childhood malignant neoplasm colon carcinoma colonic neoplasm colorectal cancer germ cell tumor Neoplasms, Germ Cell and Embryonal neuroblastoma precancerous condition rectal cancer rectal neoplasm sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Colon cancer Germ cell cancer Neuroblastoma Rectal cancer Sarcoma

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.